Human parainfluenza viruses medical therapy

Jump to navigation Jump to search

Human parainfluenza viruses Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Human parainfluenza viruses from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Human parainfluenza viruses medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Human parainfluenza viruses medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Human parainfluenza viruses medical therapy

CDC on Human parainfluenza viruses medical therapy

Human parainfluenza viruses medical therapy in the news

Blogs on Human parainfluenza viruses medical therapy

Directions to Hospitals Treating Human parainfluenza viruses

Risk calculators and risk factors for Human parainfluenza viruses medical therapy

Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.

Antimicrobial regimen

  • Parainfluenza virus[1]
  • 1. Adults
  • Preferred regimen: Ribavirin PO/IV 10 mg/kg q8h
  • Day 1: Start with 600 mg loading dose,then 200 mg q8h
  • Day 2: 400 mg q8h
  • Day 3: Increase the dose to a maximum of 10 mg/kg q8h
  • 1.1 In case of adverse events
  • Preferred regimen: Decrease dose or discontinue Ribavirin
  • 1.2 Creatinine clearance
  • 30–50 mL/min: Ribavirin PO/IV maximal 200 mg q8h
  • 10–30 mL/ min: No recommendation can be given

References

  1. Hirsch HH, Martino R, Ward KN, Boeckh M, Einsele H, Ljungman P (2013). "Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis and treatment of human respiratory syncytial virus, parainfluenza virus, metapneumovirus, rhinovirus, and coronavirus". Clin Infect Dis. 56 (2): 258–66. doi:10.1093/cid/cis844. PMC 3526251. PMID 23024295.

Template:WH Template:WS